Austria’s Apeiron To Attack COVID-19 At Its Entry Point
Phase II Study Starts In Three European Countries
Executive Summary
Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark.
You may also be interested in...
Coronavirus Update: Searching For A Treatment
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
New Standard Of Care Secures EU OK For Neuroblastoma Drug
Changes in the EU in the standard of care for high-risk neuroblastoma has resulted in EUSA Pharma’s monoclonal antibody being approved by the European Commission under exceptional circumstances.
GSK Hunts for Novelty By Paying £11m To Apeiron In A Respiratory Deal
The privately owned Austrian biotech attracts GSK to a Phase I ARDS biologic.